TABLE 2

Clinical characteristics of 5 of the patients that showed a significant cross-neutralizing response in the first 6 months of infection

ParameterValue fora:
DET 887DET 909DET 002DET 802DET 1505
Time since infection (days)9677174180119
Infection subgroupEarly recentEarly recentLate recentLate recentLate recent
% viruses neutralized (extended panel)34.615.319.234.626.9
No. of subtypes neutralized63444
GenderMaleMaleMaleMaleMale
Age (yr)4226433126
OriginWestern EuropeWestern EuropeWestern EuropeWestern EuropeWestern Europe
Transmission routeMSMMSMIDUBisexualHeterosexual
Test for recent infection (<180 days)PositivePositivePositivePositiveND
Western blot (p31 band) resultNegativeNegativeNDNDND
Symptomatic infectionYesYesNoNoNo
Fiebig stageVVVIVIVI
Subtype (retrotranscriptase/protease)B/BB/BB/CRF02AGB/BB/B
Viral tropismDualR5NDR5R5
CD4 (cells/μl)653234536780216
CD8 (cells/μl)6581,4582,642ND445
CD4+/CD8+0.990.160.20ND0.49
VL (copies/ml)76,311111,008148,0005,27124,630
Log10 VL4.885.055.173.724.39
  • a ND, not determined.